Skip to content

PressReach

SEARCH icon
  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos
Search

SEARCH FOR AN ARTICLE

  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos

PressReach

icon

      HomeAstraZeneca

      AstraZeneca

      AstraZeneca’s Imfinzi Got Approved by the FDA to Treat Cancer of the Biliary Tract.
      Investing News

      AstraZeneca’s Imfinzi Got Approved by the FDA to Treat Cancer of the Biliary Tract.

      September 6, 2022
      China Approves Forxiga From AstraZeneca for Renal Disease With or Without Type 2 Diabetes
      Investing News

      China Approves Forxiga From AstraZeneca for Renal Disease With or Without Type 2 Diabetes

      September 5, 2022
      Japan Approves AstraZeneca’s Evusheld for the Treatment of COVID
      Investing News

      Japan Approves AstraZeneca’s Evusheld for the Treatment of COVID

      August 31, 2022

       

      LATEST NEWS

      • Investing News HP to Cut 6,000 Jobs Amid Restructuring
      • Investing News Dell’s Q3 2026 Earnings Analysis
      • Investing News Workday Q3 Earnings Report 2026 Insights
      • Investing News Alibaba’s AI Boosts Cloud Sales
      • Investing News Best Buy Q3 2026 Earnings Report Insights

      PressReach

      All logos, trade names and/or trademarks, artwork and associated imagery are trademarks and/or copyright material of their respective owners.

      • Advertisers
      • Privacy Policy
      • Terms of Use
      • DMCA Policy
      • Disclaimer
      • Contact Us

      SUBSCRIBE

      To get email updates from PressReach.

      I want e-mail alerts, updates, and offers and agree to the PressReach privacy policy.

      Market Jar Media Inc. © 2025